Compugen Ltd
Company Profile
Business description
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Contact
26 Harokmim Street
Building D, Azrieli Center
Holon5885849
ISRT: +972 37658585
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 32.60 | 0.37% |
| CAC 40 | 8,121.35 | 35.30 | 0.44% |
| DAX 40 | 24,096.39 | 135.80 | 0.57% |
| Dow JONES (US) | 48,211.67 | 325.70 | 0.68% |
| FTSE 100 | 9,782.15 | 7.83 | 0.08% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 23,026.72 | 333.40 | 1.47% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,256.77 | 39.14 | -0.29% |
| S&P 500 | 6,789.01 | 67.58 | 1.01% |
| S&P/ASX 200 | 8,588.20 | 31.70 | 0.37% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |